Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-CLAUD: Neoadjuvant Zolbetuximab + DOS in Gastric Cancer
NCT06732856Phase 2Recruiting
- Sponsor
- Asan Medical Center
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zolbetuximab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Asan Medical Center. Primary endpoints: Recommended Phase 2 Dose at 1 year, R0 Resection Rate at 1 year and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
zolbetuximab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06732856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06732856.